The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Nutra Pharma's Revenue for the
three
months ended in Sep. 2022 was $0.11 Mil. Nutra Pharma's average Accounts Receivable for the
three
months ended in Sep. 2022 was $0.03 Mil.
Hence, Nutra Pharma's Receivables Turnover for the
three
months ended in Sep. 2022 was 3.16.
Nutra Pharma Receivables Turnover Historical Data
The historical data trend for Nutra Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nutra Pharma's Receivables Turnover
For the Drug Manufacturers - Specialty & Generic subindustry, Nutra Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nutra Pharma's Receivables Turnover Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nutra Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Nutra Pharma's Receivables Turnover falls into.
Nutra Pharma Receivables Turnover Calculation
Receivables Turnover measures the number of times a company collects its average accounts receivable balance.
Nutra Pharma's Receivables Turnover for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Nutra Pharma Receivables Turnover Related Terms
Thank you for viewing the detailed overview of Nutra Pharma's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Nutra Pharma Corp operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. It also develops proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Some of its drug names are Cobroxin, Nyloxin, RPI-78M, RPI-MN and Pet Pain-Away.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NPHC has been successfully added to your 